Israel Englander Jounce Therapeutics, Inc. Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.9 - $1.85 $1.2 Million - $2.46 Million	-1,328,681 Reduced 72.66%	500,000 $925,000
Q4 2022 Feb 14, 2023	BUY	$0.64 - $1.99 $1.17 Million - $3.64 Million	1,828,681 New	1,828,681 $2.03 Million
Q2 2022 Aug 15, 2022	BUY	$2.8 - $7.67 $231,669 - $634,608	82,739 New	82,739 $251,000
Q1 2022 May 16, 2022	SELL	$6.01 - $8.54 $417,935 - $593,871	-69,540 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$7.11 - $9.64 $1.22 Million - $1.66 Million	-171,685 Reduced 71.17%	69,540 $581,000
Q3 2021 Nov 15, 2021	SELL	$5.04 - $8.73 $1.09 Million - $1.9 Million	-217,091 Reduced 47.37%	241,225 $1.79 Million
Q2 2021 Aug 16, 2021	BUY	$6.58 - $10.66 $1.84 Million - $2.99 Million	280,088 Added 157.15%	458,316 $3.12 Million
Q1 2021 May 17, 2021	BUY	$6.73 - $13.87 $877,141 - $1.81 Million	130,333 Added 272.12%	178,228 $1.83 Million
Q4 2020 Feb 16, 2021	BUY	$6.37 - $10.33 $159,033 - $257,898	24,966 Added 108.88%	47,895 $335,000
Q3 2020 Nov 16, 2020	BUY	$4.58 - $10.95 $32,902 - $78,664	7,184 Added 45.63%	22,929 $187,000
Q2 2020 Aug 14, 2020	SELL	$4.17 - $7.58 $210,088 - $381,887	-50,381 Reduced 76.19%	15,745 $109,000
Q1 2020 May 14, 2020	BUY	$2.91 - $8.7 $5,345 - $15,981	1,837 Added 2.86%	66,126 $314,000
Q4 2019 Feb 14, 2020	SELL	$2.81 - $9.21 $264,966 - $868,447	-94,294 Reduced 59.46%	64,289 $561,000
Q3 2019 Nov 14, 2019	BUY	$3.33 - $4.93 $528,081 - $781,814	158,583 New	158,583 $528,000
Q1 2019 May 14, 2019	SELL	$3.43 - $6.87 $747,822 - $1.5 Million	-218,024 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$2.69 - $6.71 $1.14 Million - $2.83 Million	-422,237 Reduced 65.95%	218,024 $735,000
Q3 2018 Nov 14, 2018	SELL	$6.5 - $8.37 $252,954 - $325,726	-38,916 Reduced 5.73%	640,261 $4.16 Million
Q2 2018 Aug 14, 2018	BUY	$7.27 - $21.88 $3.15 Million - $9.48 Million	433,281 Added 176.2%	679,177 $5.2 Million
Q1 2018 May 15, 2018	SELL	$13.4 - $28.4 $1,675 - $3,550	-125 Reduced 0.05%	245,896 $5.5 Million
Q4 2017 Feb 14, 2018	BUY	$12.52 - $17.82 $2.33 Million - $3.32 Million	186,068 Added 310.36%	246,021 $3.14 Million
Q3 2017 Nov 14, 2017	BUY	$11.17 - $16.99 $669,675 - $1.02 Million	59,953	59,953 $934,000

Others Institutions Holding JNCE

# of Institutions

Shares Held

720K

Call Options Held

Put Options Held

View Full List

About Jounce Therapeutics, Inc.

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

More about JNCE

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account